Reaction profile

The FDA adverse-event record for necrosis nos

88 FDA adverse-event reports reference necrosis nos (VeDDRA 2889). Plate codes and volume neighbourhood below; species, breeds, and drugs follow.

#1455 of 2,481
by report volume (all reactions)
88
reports citing this reaction
43.2%
death-coded share
Dog
most-affected species

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Necrosis NOS has 88 reports now versus 86 in that prior snapshot: 2 more (2.3%).

Report change
+2
Death-coded reports
+1
Death-coded share
+0.2 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Necrosis NOS changes

FDA AER · VeDDRA plate

Code 2889 VOL-LOW

VOL-LOW · DEATH-HOT · MID-PACK · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL

  • VOL-LOW 88 reports
  • DEATH-HOT 43.2%
  • MID-PACK #1455/2481
  • PHOTO-FINISH Difficulty in micturi…
  • SPECIES-DOG Dog · 70
  • DRUG-LEAD Gabapentin · 24
  • DESK-WIDE 20 breeds
  • BOOK-FULL 8/8 fields

Nearest volume peer: Difficulty in micturition (±0 reports)

Upper-third death-coded share drives the outcome stamps on this plate; volume band, corpus rank, and co-report peers follow. Not a clinical diagnosis.

Report-volume neighbourhood around Necrosis NOS

Highest and lowest poles plus nearest volume peers, not a full 2,500-reaction corpus board reprint.

Vomiting · highest174348Difficulty in micturi… · near88Excessive sweating · near88Necrosis NOS · this reaction88RED BLOOD CELLS(RBC)… · near88Bone marrow disorder… · near87Urinary tract neoplas… · low…10
FDA AER report volume · neighbourhood around Necrosis NOS

Necrosis NOS: high death-coded share in the FDA AER plate

Signature read: Necrosis NOS's 43.2% death-coded share is among the highest in the openFDA reaction corpus. Report volume sits in the middle third of the reaction corpus. Death-coded share is upper-third: 38 of 88 reports (43.2% of named reports). Nearest volume peer: Difficulty in micturition (±0 reports). Lead species Dog (70). Lead co-reported drug Gabapentin (24).

Read these counts as reporting volume, not risk: per our methodology, A high death-coded share in FDA filings does not prove causation; co-reporting is voluntary temporal association only. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.

Species Most Affected

Dog 70
Cat 14
Cattle 3
Horse 1

Breeds Most Affected

Domestic Shorthair 11
Retriever - Labrador 7
Crossbred Canine/dog 6
Dog (unknown) 5
Pit Bull 5
Shepherd Dog - German 5
Beagle 4
Shih Tzu 3
Maltese 3
Terrier - Yorkshire 3

Associated Drugs

Gabapentin 24
Tigilanol Tiglate 20
Maropitant Citrate 17
Bedinvetmab 14
Prednisone 12
Diphenhydramine 12
Buprenorphine 12
Famotidine 11
Carprofen 10
Propofol 9
Midazolam 8
Dexmedetomidine 7
Butorphanol 6
Butorphanol Tartrate 6
Bupivacaine 5
Anesthetic (Unknown) 5
Tramadol 5
Dexmedetomidine Hydrochloride 5
Trazodone 5
Robenacoxib 4

Nationwide reactions with similar profiles

Two openFDA-derived peer sets for Necrosis NOS, both floored at ≥50 reports so the neighborhoods stay in the advertised mass (the volume chart above is the unfloored photo-finish strip).

Similar death-coded share

Nearest other reactions by death-coded share (43.2% here), distinct from the volume row.

What to do with this reaction

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Necrosis NOS (#1455 of 2,481 by report volume); death-coded 43.2%. PlainBreed reaction plate · death-coded share stamp 43.2% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →